Verastem, Inc. (VSTM) Delivers Positive Preliminary Data for VS-7375 in Mutant Solid Tumors Treatment

Verastem, Inc. (NASDAQ:VSTM) is one of the top long-term biotechnology stocks to buy. On October 23, Verastem, Inc. (NASDAQ:VSTM) reported positive preliminary results from an ongoing phase 1/2a dose-escalation trial of vs-7375, an oral KRAS G12D (on/off) inhibitor, in patients with KRAS G12D-mutant solid tumors. Verastem, Inc. (VSTM) Delivers Positive Preliminary Data for VS-7375 in Mutant Solid Tumors Treatment The preliminary safety and tolerability data indicate that VS-7375 can be administered at ef ...